This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly's (LLY) Erbitux Gets FDA Nod for Expanded Use in CRC
by Zacks Equity Research
Eli Lilly (LLY) secures FDA approval for Erbitux combined with Pfizer's Braftovi to treat BRAF V600E mutation-positive metastatic CRC in adult patients who received prior therapy.
Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails
by Zacks Equity Research
Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot
by Kinjel Shah
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
by Zacks Equity Research
AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam
by Zacks Equity Research
Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Lilly (LLY) to Supply COVID Cocktail Drug to EU Countries
by Zacks Equity Research
Elli Lilly (LLY) is set to supply 220,000 doses of its COVID-19 antibody cocktail to European Union member nations, following approval.
Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer
by Zacks Equity Research
The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
by Zacks Equity Research
Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.
Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers
by Zacks Equity Research
The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.
Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail
by Zacks Equity Research
FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.
AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
by Kinjel Shah
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
Regeneron, Lilly Get New COVID Drug Deals From Government
by Zacks Equity Research
Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY
by Zacks Equity Research
Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW
by Zacks Equity Research
Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.
The Zacks Analyst Blog Highlights: Eli Lilly, Exxon Mobil, Lowe's, General Electric and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Exxon Mobil, Lowe's, General Electric and Anthem
Top Research Reports for Eli Lilly, Exxon Mobil & Lowe's
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil Corporation (XOM), and Lowe's Companies, Inc. (LOW).
Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Lilly's (LLY) Jardiance for heart failure with preserved ejection fraction (HFpEF).
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs
by Kinjel Shah
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down
by Zacks Equity Research
Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.
Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study
by Zacks Equity Research
Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
by Zacks Equity Research
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment
by Zacks Equity Research
The FDA approves Impel's (IMPL) Trudhesa nasal spray for the acute treatment of migraine with or without aura in adults.
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.